“The knowledge, experience and insights of Drs. Allison and Sharma will provide valuable contributions to the direction and prioritization of our CAB development programs. In particular, their advice will enhance our decisions and design of combination CAB immunotherapies and CAB bispecifics,” said Jay M. Short.
Among Dr. Allison’s most notable discoveries in his distinguished career studying the regulation of T cell responses, are the determination of the T cell receptor structure and that CD28 is the costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones.
His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models, and launched the emerging field of immune checkpoint blockade therapy for cancer.
These proteins can be mAbs, enzymes and other proteins designed with functions dependent on changes in microphysiological conditions both outside and inside cells.
These cancerous microenvironments are primarily a result of the well understood unique glycolytic metabolism associated with cancer cells, referred to as the Warburg Effect.
CAB proteins are designed to deliver their therapeutic payload and/or recruit the immune response in specific and selected locations and conditions within the body and to be active only in the presence of a particular cellular microenvironment.
BioAtla develops novel monoclonal antibody and other protein therapeutic product candidates designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies.